Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 62   

Articles published

ARNA 4.19 +0.07 (1.70%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the ...
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Arena Pharmaceuticals APD811 Pipeline Advancement The First Of Several ...
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) have been consolidating in an ever tighter range since the June 27th approval of their obesity drug BELVIQ.
Related articles »  
Arena Pharma (ARNA), Vivus (VVUS): Which Hedge Funds Made the Wrong ...
Since the end of 2Q, the very popular biopharma companies, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and Vivus, Inc. (NASDAQ:VVUS) have performed poorly.
Can Orexigan Benefit From Possible FDA Changes In Approval?  Seeking Alpha
Related articles »  
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
Now Could Be The Time To Speculate On Achillion Pharmaceuticals
That will cost Achillion a large percentage of all future profits (still not an awful deal at this point), just as Arena had to do.
FDA Considers Faster Approval Process for Obesity Drugs
Arena Pharmaceuticals Inc. (ARNA:US)'s Belviq weight-loss pill and Vivus Inc. (VVUS:US)'s Qsymia may have been approved earlier for use by morbidly obese people had such a path existed.
Related articles »  
Eisai's Epilepsy Drug Helps Obese Patients Reduce Weight
The efficacy was similar to Roche Holding AG (ROG)'s Xenical and Arena Pharmaceuticals Inc. (ARNA:US)'s Belviq. Side effects such as mood changes and memory problems occurred more frequently than with a placebo, the authors of the study at Duke ...
Related articles »  
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
Related articles »  
3 Best Biotech Stocks For This Week (Part VII)
... symptomatic neurogenic orthostatic hypotension. So in this article, I will write about the reasons to take a speculative position in Cell Therapeutics Inc (NASDAQ:CTIC), Arena Pharmaceuticals (NASDAQ:ARNA) and Chelsea Therapeutics (NASDAQ:CHTP).
IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry
... prostate cancer; Onyx Pharmaceuticals (NASDAQ:ONXX) for Kyprolis that treats a rare blood cancer; VIVUS Inc. (NASDAQ:VVUS) for Qsymia (TM) for the treatment of obesity; Arena Pharmaceuticals (NASDAQ:ARNA) for Lorcaserin that also treats obesity; ...
Related articles »